It's diagnostics, stupid.
To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop molecular diagnostics to better identify the patients that respond to expensive targeted therapies. Opportunities and obstacles in the development of such drug response biomarkers are discussed here.
Bernards
René
R
Division of Molecular Carcinogenesis, Center for Biomedical Genetics and Cancer Genomics Center, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. r.bernards@nki.nl
D054316:Biomarkers, Pharmacological / Q000032:analysis*; D003695:Delivery of Health Care / Q000191:economics; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000191:economics; D057089:Pathology, Molecular
D054316:Biomarkers, Pharmacological